SynKIR-310 for advanced B-cell lymphoma
Part of Blood & lymphatic, Cancer, Digestive system, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with B-cell non-Hodgkin lymphoma (B-NHL).
- You have already had CAR T-cell therapy, or you cannot get it.
- Your lymphoma has come back or not responded after at least 2 prior treatments.
- You are generally well enough to do daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new type of cell therapy called CAR NK cells that are designed to find and attack lymphoma cells carrying a marker called CD70. It is for people whose lymphoma either did not go away after the first treatment or came back within a year.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.